Neuren Pharmaceuticals Ltd
ASX:NEU
Neuren Pharmaceuticals Ltd
Cash from Financing Activities
Neuren Pharmaceuticals Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash from Financing Activities
AU$3.6m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-18%
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash from Financing Activities
-AU$431.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cash from Financing Activities
AU$36.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
11%
|
CAGR 10-Years
46%
|
|
Probiotec Ltd
ASX:PBP
|
Cash from Financing Activities
-AU$11.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash from Financing Activities
AU$231.6k
|
CAGR 3-Years
-70%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Vita Life Sciences Ltd
ASX:VLS
|
Cash from Financing Activities
-AU$2.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-15%
|
See Also
What is Neuren Pharmaceuticals Ltd's Cash from Financing Activities?
Cash from Financing Activities
3.6m
AUD
Based on the financial report for Dec 31, 2023, Neuren Pharmaceuticals Ltd's Cash from Financing Activities amounts to 3.6m AUD.
What is Neuren Pharmaceuticals Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-18%
The average annual Cash from Financing Activities growth rates for Neuren Pharmaceuticals Ltd have been -43% over the past three years , -21% over the past five years , and -18% over the past ten years .